Willenbring Lab »  Lab Members »  Postdoctoral Fellows »  Milad Rezvani, M.D.

Milad Rezvani, M.D.

Postdoctoral Fellow

Contact Information

Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research
University of California San Francisco
35 Medical Center Way
RMB-902D, Pod A
San Francisco, CA 94143
Lab phone: 415 476 2420
Cell phone: 415 933 9238
Open Popup
  • Wilhelm-Raabe-Schule, Lower Saxony, Hannover, Germany, University-entrance diploma, 2004
  • Hannover Medical School, Germany, Preclinical Medical Examination, 2006
  • University of Freiburg, Germany, German Medical State Examination, 2011
  • 04/2015 - 08/2016 Clinical guest student at USCF Medical Center at Mission Bay, Pediatric Hepatology and San Francisco General Hospital, Adult GI division
  • University of Freiburg, Germany, Doctoral Dissertation, "Role of Matrix Metalloproteinases in the genetics of Bronchopulmonary Dysplasia and Neonatal Respiratory Distress Syndrome", 2013
  • Biomedical Exchange Program (BMEP)-Scholarship funded by the German Academic Exchange Service (DAAD) for research on liver cell therapy at the Willenbring lab at the University of California San Francisco (UCSF), 2012-2013
  • Biomedical Exchange Program (BMEP)-Scholarship funded by the German Academic Exchange Service (DAAD), Research Fellowship of the German Research Foundation
  • Willenbring laboratory, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, UCSF, Research Foci: 1. Therapeutic liver repopulation with hepatocytes generated from human fibroblasts, 2. In vivo hepatic reprogramming of myofibroblasts in liver fibrosis and cirrhosis
  • Adult and pediatric Hepatology and Gastroenterology
  • Barrett's Esophagus
  • Biliary Diseases
  • Bronchopulmonary Dysplasia
  • Cirrhosis
  • Dysplasia
  • Gene Therapy
  • Gene Vectors
  • Genetics
  • Liver Cell Therapy
  • Liver Fibrosis
  • Liver Regeneration
  • Lung Development
  • Lung Diseases
  • Lung Fibrosis
  • Metaplasia
  • Stem Cells

Milad Rezvani, M.D. studied Medicine in Hannover/Germany and Freiburg/Germany and also worked as a volunteer in numerous Primary Health Care projects in Ghana, Nepal, Peru and Argentina. As a graduate student he investigated the effect of genetic variants in endoderm and lung development on neonatal lung diseases. As an exchange student he came to UCSF to work on generating therapeutic human liver cells from readily available skin cells. As a Postdoctoral Fellow of the German Research Foundation he continued working in the Willenbring lab to develop potential therapies for chronic liver diseases, particularly by in vivo reprogramming of cirrhosis-causing myofibroblasts into hepatocytes.

  1. Rezvani M, Español-Suñer R, Malato Y, Dumont L, Grimm AA, Kienle E, Bindman JG, Wiedtke E, Hsu BY, Naqvi SJ, Schwabe RF, Corvera CU, Grimm D, Willenbring H. In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis. Cell Stem Cell. 2016 Jun 2; 18(6):809-16. View in PubMed
  2. Rezvani M, Grimm AA, Willenbring H. Assessing the therapeutic potential of lab-made hepatocytes. Hepatology. 2016 Jul; 64(1):287-94. View in PubMed
  3. Desai SS, Tung JC, Zhou VX, Grenert JP, Malato Y, Rezvani M, Español-Suñer R, Willenbring H, Weaver VM, Chang TT. Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha. Hepatology. 2016 Jul; 64(1):261-75. View in PubMed
  4. Zhu S, Rezvani M, Harbell J, Mattis AN, Wolfe AR, Benet LZ, Willenbring H, Ding S. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature. 2014 Apr 3; 508(7494):93-7. View in PubMed
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Milad Rezvani, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.
  1. 11/2015: Presidential Plenary Session of the The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, selected oral presentation: "In vivo reprogramming of myofibroblasts into hepatocytes as a therapy for liver fibrosis"